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Abstract
Background: Neuraminidase (NA) is a prominent surface antigen of Influenza viruses, which helps in release of
viruses from the host cells after replication. Anti influenza drugs such as Oseltamivir target a highly conserved
active site of NA, which comprises of 8 functional residues (R118, D151, R152, R224, E276, R292, R371 and Y406) to
restrict viral release from host cells, thus inhibiting its ability to cleave sialic acid residues on the cell membrane.
Reports on the emergence of Oseltamivir resistant strains of H1N1 Influenza virus necessitated a search for
alternative drug candidates. Pleconaril is a novel antiviral drug being developed by Schering-Plough to treat
Picornaviridae infections, and is in its late clinical trials stage. Since, Pleconaril was designed to bind the highly
conserved hydrophobic binding site on VP1 protein of Picorna viruses, the ability of Pleconaril and its novel
substituted derivatives to bind highly conserved hydrophobic active site of H1N1 Neuraminidase, targeting which
oseltamivir has been designed was investigated.
Result: 310 novel substituted variants of Pleconaril were designed using Chemsketch software and docked into the
highly conserved active site of NA using arguslab software. 198 out of 310 Pleconaril variants analyzed for docking
with NA active site were proven effective, based on their free binding energy.
Conclusion: Pleconaril variants with F, Cl, Br, CH3, OH and aromatic ring substitutions were shown to be effective
alternatives to Oseltamivir as anti influenza drugs.
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Background
Most of the early antiviral drugs were discovered after
screening large number of possible drug compounds
using trial and error method. Lately, this approach has
been largely replaced by rational drug design, in which, a
target viral protein is identified for the drug [1]. A
detailed picture of the 3 dimensional structure of the
protein can be derived using In-silico computational
techniques and a target site in the protein can be selected
[2]. In influenza viruses, NA surface antigen plays a vital
role in releasing the virus from the host cell during the
budding stage [3]. Ever since the crystal structure of NA
was determined, it is used as a target protein for many
drug compounds. Oseltamivir (Figure 1) is one such
approved anti-influenza drug compound that targets the
highly conserved NA active site of H1N1 Influenza virus
which comprises of 8 functional residues (R118, D151,
R152, R224, E276, R292, R371 and Y406) [4,5]. The
recent outbreaks of H1N1 and reports of oseltamivir
resistant strains have necessitated the need to find effec-
tive alternatives to the existing anti-influenza drugs [6].
Pleconaril (Figure 2) is a novel antiviral drug being
developed by Schering-Plough to treat Picornaviridae
infections, and is in its late clinical trials stage [7].
Highly conserved hydrophobic pocket of VP1 protein,
which forms a part of picornaviral capsid, is the target
for Pleconaril activity. In enteroviruses, this prevents the
virus from exposing its RNA, and in rhinoviruses it pre-
v e n t st h ev i r u sf r o ma t t a c h i n gi t s e l ft ot h eh o s tc e l l[ 8 ] .
However, to date, to the best of our knowledge there is
no study reporting the activity of Pleconaril against
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the highly conserved hydrophobic binding site on VP1
protein of Picorna viruses, the ability of Pleconaril and
its novel substituted derivatives to bind highly conserved
hydrophobic active site of H1N1 Neuraminidase, target-
ing which oseltamivir has been designed was investi-
gated in this present study.
Molecular modeling tools help in generating new can-
didate drug molecules within a short span of time. After
generation of new possible drug candidates, the drug
and target protein interaction dynamics can be predicted
by carrying out a docking analysis. The knowledge so
derived is used to predict the strength of association or
binding affinity between the two molecules based on
scoring functions.
A database of potential drug molecules and target pro-
tein structure serve as inputs for docking analysis. The
success of the docking analysis is determined by scoring
function and search algorithm [9], which helps in deter-
mining the compatibility between the drug and its target
protein. This technique is being used extensively to pre-
dict the geometries of different bimolecular complexes
[10]. Scoring function predicts the strength of the bind-
ing affinity between ligand and the protein based on the
complex geometry [11] and search algorithm analyzes
the drug molecule for different binding positions with
its target molecule, each binding position, which is
termed a “pose”, is used to generate the snapshot of
interactions [12].
In our present study, a database of 310 novel substituted
Pleconaril variants was built by altering the side chains
and substituting different aromatic rings into the original
Pleconaril molecule. Molecular docking analysis was per-
formed to visualize the interaction of each of these var-
iants with target molecule. An attempt was made to
identify Pleconaril variants with best NA binding ability.
Methods
1. Preparation of Receptor
The crystal structure of NA of 1918 Spanish flu (A/Bre-
vig Mission/1/18 H1N1) virus (PDB ID: 3BEQ) was
obtained from Protein Data Bank (PDB) [13] with a
resolution factor of 1.64 Å and the method incorporated
is X-Ray diffraction [14]. Before docking, the crystal
structure of the protein was cleaned by removing the
water molecules and hydrogen atoms were added to this
target protein for correct tautomeric and ionization
states of amino acid residues. The modified structure so
obtained was saved in .pdb format and used for all
docking studies.
2. Preparation of Ligands
Oseltamivir (Compound ID 65028) [15] and Pleconaril
(Compound ID 1684) [16] were obtained from pubchem
database [17]. Using ACDLABS ChemSketch 11.0 [18]
software, 310 novel substituted derivatives of Pleconaril
were designed using Cl, F, Br, CH3 and OH functional
groups as substitutes on R, R1, R2, R3, R4, R5, and R6
positions of 11 basic Pleconaril variants (Figure 3).
Figure 1 Structure and properties of Oseltamivir.
Figure 2 Structure and properties of Pleconaril. Figure 3 11 Basic variants of Pleconaril.
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were added to each molecule and fidelity of all bonds
was checked using “add hydrogens” and “Clean Hybridi-
zation” options respectively. Geometry optimization was
done using UFF [20-24] Molecular Mechanics (MM)
method. Finally Oseltamivir, Pleconaril and all the novel
substituted Pleconaril derivatives were saved in .mol for-
mat for further docking studies.
3. Determination of Active site
The highly conserved active site of NA, which comprises of
8 functional residues (R118, D151, R152, R224, E276, R292,
R371 and Y406) targeting which oseltamivir has been
designed was considered as active site for docking analysis.
4. Docking
Docking between receptor and ligands was performed
using “Dock a Ligand” option of arguslab 4.0.1 software.
A spacing of 0.4 Å between the grid points was used.
“ArgusDock” was selected as docking engine. “Regular
precision” was selected in docking precision menu,
“Dock” was chosen as calculation type, “Flexible” for the
ligand and “AScore” was used as the scoring function. A
maximum of 150 poses were allowed to be analyzed,
binding site box was set to 25 × 25 × 25 angstroms to
encompass the entire active site. Each docking run was
repeated three times to get best results. Resulted docked
molecules were saved in .pdb format and all the docking
images were generated using Accelrys
® Discovery Studio
3.0 Visualizer software [25].
Results and discussion
All the 310 variants of Pleconaril molecule were ana-
lyzed for binding with the active site of NA. 198 out of
these were found to have optimum binding efficiency,
based on the binding energy calculations in comparison
with Oseltamivir.
Further investigations showed that Oseltamivir formed
6 hydrogen bonds with TYR 406, GLU 277, ARG 224
(Figure 4) and Pleconaril formed 6 hydrogen bonds with
S E R2 4 6 ,P R O2 4 5 ,A R G1 1 8a m i n oa c i dr e s i d u e s
(Figure 5), whereas the best Pleconaril variant formed 9
hydrogen bonds with ARG 118, ASN 347, ARG 371 and
GLU 277 amino acid residues of NA active site. More-
over the central benzene ring and furan ring of the best
Pleconaril variant played a major role in stabilizing the
Figure 4 A) Binding of oseltamivir (Blue) into the active site of NA. B) Amino acid residues (Yellow) in the active site of NA interacting with
Oseltamivir by hydrogen bonds (dotted red line) using -7.71113 K.Cal./mol. of binding energy.
Figure 5 A) Binding of Pleconaril (Blue) into the active site of NA. B) Amino acid residues (Yellow) in the active site of NA interacting with
Pleconaril by hydrogen bonds (dotted red line) using -7.77243 K.Cal./mol. of binding energy.
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Page 3 of 7ligand receptor complex by pi-cation interactions with
amino acid residues ARG 118 and ARG 371 along with
hydrogen bonds (Figure 6).
Pleconaril derivative (Numbered 3 in Table 1), with a
binding energy of -9.97543 K.cal/mol. showed the least
possible binding energy of all variants analyzed.
Whereas the binding energy of oseltamivir, the original
NA inhibitor, was found to be -7.7113 K.cal/mol. 44
variants of Pleconaril were found to be having binding
energy around -9.0 K.cal/mol. 10 best variants out of
Figure 6 A) Binding of Best Pleconaril variant (Blue) into the active site of NA. B) Amino acid residues (Yellow) in the active site of NA
interacting with Best Pleconaril variant by hydrogen bonds (dotted red line) and pi-cationic interactions (Solid Black line) using -9.97543 K.Cal./
mol. of binding energy.
Table 1 Structure, molecular formula, binding energies of Oseltamivir, Pleconaril and best variant of pleconaril
S. No Structure of molecule Molecular formula Binding energy in K.cal./mol.
1. C16H28N2O4 -7.71113
2. C18H18F3N3O3 -7.77243
3. C21H21Cl3O9 -9.97543
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Page 4 of 7Table 2 Structure, molecular formula, binding energies of 10 best variants of pleconaril
S. No Structure of molecule Molecular formula Binding energy in K.cal./mol.
1. C21H21Cl3O4S2 -9.90775
2. C21H21F3O7S2 -9.90392
3. C21H21Br3O7S2 -9.90239
4. C21H21BrClFO7S2 -9.69162
5. C23H25BrClFO7S2 -9.67661
6. C21H21Cl3O7S2 -9.60862
7. C21H21Br3O9 -9.57821
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were selected because of their least binding energies, as
the drug molecules with the least binding energy are
generally considered to be having high binding efficien-
cies. Analysis of these 44 variants in further established
that furan and thiophene substitutions along with the
presence of central benzene ring in the main molecule
played an important role in determining the binding
affinity of the drug variants.
Conclusion
Computer aided drug designing and molecular docking
analysis are highly effective in creating and analyzing new
candidate drug molecules. 198 out of 310 Pleconaril var-
iants analyzed for docking with NA active site were proven
effective. Pleconaril variants with F, Br, CH3, Cl, OH and
aromatic ring substitutes showed higher levels of NA
binding ability. Several interactions such as hydrogen
bonds, hydrophobic, hydrophilic interactions, electrostatics
and Vanderwaal forces are thought to have played an
important role in stabilizing the drug and target complexes
based on the theoretical modeling. Thus, based on the
above results we propose Pleconaril variants numbered 3,
4 and 11 (Figure 4) with F, Br, CH3, Cl and OH substitu-
tions at R, R1, R2, R3, R4, R5, and R6 positions have a
definite potential to be developed as lead compounds for
H1N1 Influenza virus. However as it is only a preliminary
In-silico investigation in modifying the Pleconaril molecule
for anti-influenza activity, further In-vivo validation and
conformation of the present findings is required.
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